Total Payments
$5,407
2024 Payments
$448.59
Companies
32
Transactions
252
Medicare Patients
16,491
Medicare Billing
$903,924
Payment Breakdown by Category
Food & Beverage$5,336 (98.7%)
Education$71.20 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,336 | 250 | 98.7% |
| Education | $71.20 | 2 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1,474 | 83 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $850.09 | 28 | $0 (2024) |
| Novo Nordisk Inc | $749.48 | 30 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $300.35 | 10 | $0 (2021) |
| Merck Sharp & Dohme LLC | $274.57 | 15 | $0 (2023) |
| Lilly USA, LLC | $273.51 | 13 | $0 (2023) |
| PFIZER INC. | $235.96 | 14 | $0 (2020) |
| Amarin Pharma Inc. | $166.90 | 5 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $148.99 | 5 | $0 (2021) |
| Daiichi Sankyo Inc. | $144.94 | 4 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $448.59 | 18 | AstraZeneca Pharmaceuticals LP ($193.21) |
| 2023 | $485.97 | 24 | GlaxoSmithKline, LLC. ($208.72) |
| 2022 | $498.94 | 25 | GlaxoSmithKline, LLC. ($314.70) |
| 2021 | $797.62 | 43 | GlaxoSmithKline, LLC. ($295.70) |
| 2020 | $928.75 | 24 | AstraZeneca Pharmaceuticals LP ($336.51) |
| 2019 | $660.30 | 36 | GlaxoSmithKline, LLC. ($191.14) |
| 2018 | $913.68 | 49 | GlaxoSmithKline, LLC. ($194.99) |
| 2017 | $673.45 | 33 | Lilly USA, LLC ($187.09) |
All Payment Transactions
252 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $2.12 | General |
| Category: RESPIRATORY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $106.97 | General |
| Category: RESPIRATORY | ||||||
| 10/29/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $18.53 | General |
| Category: Insulin Pump | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/30/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $9.97 | General |
| Category: RESPIRATORY | ||||||
| 09/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: RESPIRATORY | ||||||
| 09/03/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $9.76 | General |
| Category: RESPIRATORY | ||||||
| 08/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: RESPIRATORY | ||||||
| 07/25/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: RESPIRATORY | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.42 | General |
| 06/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: Diabetes | ||||||
| 05/15/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: Respiratory | ||||||
| 05/14/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug), FARXIGA | Food and Beverage | In-kind items and services | $2.32 | General |
| Category: Respiratory | ||||||
| 05/13/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: Diabetes | ||||||
| 04/29/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Diabetes | ||||||
| 04/03/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $10.44 | General |
| Category: RESPIRATORY | ||||||
| 03/06/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/05/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $121.26 | General |
| Category: Respiratory | ||||||
| 11/30/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/21/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA, SHINGRIX | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: RESPIRATORY | ||||||
| 11/08/2023 | Merck Sharp & Dohme LLC | BELSOMRA (Drug), VERQUVO, VERQUVO | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA, SHINGRIX | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: RESPIRATORY | ||||||
| 09/08/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: RESPIRATORY | ||||||
| 08/24/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 62 | 2,906 | 5,841 | $338,153 | $155,104 |
| 2022 | 64 | 3,540 | 7,234 | $402,423 | $187,525 |
| 2021 | 80 | 4,680 | 9,298 | $606,246 | $290,476 |
| 2020 | 80 | 5,365 | 10,031 | $559,578 | $270,819 |
Total Patients
16,491
Total Services
32,404
Medicare Billing
$903,924
Procedure Codes
286
All Medicare Procedures & Services
286 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 80 | 705 | $39,255 | $27,174 | 69.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 127 | 324 | $47,030 | $24,886 | 52.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 107 | 242 | $24,600 | $14,535 | 59.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 55 | 157 | $16,605 | $9,255 | 55.7% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 24 | 24 | $28,805 | $5,881 | 20.4% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 18 | 148 | $11,230 | $5,035 | 44.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 43 | 48 | $9,620 | $4,679 | 48.6% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 149 | 274 | $11,025 | $4,497 | 40.8% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 16 | 134 | $12,180 | $4,380 | 36.0% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 25 | 49 | $7,350 | $4,236 | 57.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 52 | 52 | $15,785 | $3,705 | 23.5% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 22 | 88 | $6,600 | $3,667 | 55.6% |
| 82306 | Vitamin d-3 level | Office | 2023 | 97 | 123 | $9,255 | $3,525 | 38.1% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 152 | 268 | $7,569 | $3,470 | 45.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 147 | 295 | $8,330 | $3,048 | 36.6% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 120 | 166 | $4,346 | $2,432 | 56.0% |
| 82746 | Folic acid level, serum | Office | 2023 | 120 | 166 | $4,180 | $2,370 | 56.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 151 | 374 | $2,316 | $2,237 | 96.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 146 | 294 | $4,784 | $2,234 | 46.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 35 | 39 | $3,950 | $2,168 | 54.9% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 82 | 173 | $3,856 | $1,637 | 42.5% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 61 | 75 | $5,255 | $1,574 | 29.9% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 15 | 18 | $1,820 | $1,348 | 74.1% |
| 83735 | Magnesium level | Office | 2023 | 135 | 204 | $3,115 | $1,317 | 42.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 25 | 25 | $6,260 | $1,133 | 18.1% |
About Dr. Carlos Liotta, MD
Dr. Carlos Liotta, MD is a Family Medicine healthcare provider based in Tuscumbia, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1528270790.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carlos Liotta, MD has received a total of $5,407 in payments from pharmaceutical and medical device companies, with $448.59 received in 2024. These payments were reported across 252 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($5,336).
As a Medicare-enrolled provider, Liotta has provided services to 16,491 Medicare beneficiaries, totaling 32,404 services with total Medicare billing of $903,924. Data is available for 4 years (2020–2023), covering 286 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Other Specialties Sports Medicine
- Location Tuscumbia, AL
- Active Since 05/03/2007
- Last Updated 04/08/2016
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1528270790
Products in Payments
- TRELEGY ELLIPTA (Drug) $1,189
- FARXIGA (Drug) $467.68
- Ozempic (Drug) $466.09
- JARDIANCE (Drug) $265.13
- BELSOMRA (Drug) $183.06
- Vascepa (Drug) $166.90
- TRULICITY (Drug) $166.42
- RYBELSUS (Drug) $140.81
- AREXVY (Drug) $138.39
- AIRSUPRA (Drug) $121.26
- BREZTRI (Drug) $119.75
- XIFAXAN (Drug) $102.72
- CHANTIX (Drug) $101.30
- BREZTRI AEROSPHERE (Drug) $101.19
- Movantik (Drug) $100.00
- Repatha (Biological) $100.00
- ELIQUIS (Drug) $95.44
- ANORO (Drug) $92.27
- Rybelsus (Drug) $91.93
- VRAYLAR (Drug) $87.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.